Domain Therapeutics is a global clinical-stage biopharmaceutical company pioneering GPCR-targeting cancer immunotherapies. With over two decades of drug discovery expertise, the company is dedicated to developing innovative therapeutics that unlock the power of the immune system to combat cancer. Their unique approach focuses on reversing GPCR-mediated immunosuppression and enhancing the efficacy of existing treatments, addressing the high unmet need for cancer patients who do not respond to current therapies. Domain Therapeutics is recognized for its proprietary drug discovery platform and has established partnerships with leading pharmaceutical companies to advance its promising pipeline of first-in-class and best-in-class treatments.
Something looks off?